FDA Fast Tracks Pancreatic Cancer Drug That Doubles Survival Times
Finn's Take· TL;DR- Pancreatic cancer drug daraxonrasib doubles median survival to 13 months versus 6 months with chemotherapy in clinical trials.
- FDA granted emergency expanded access within two days, allowing patients to receive treatment before formal approval completes.
- Former Senator Ben Sasse reported 76% tumor reduction and significantly less pain after four months using the RAS inhibitor.
Revolutionary Treatment Gets Emergency Access
The FDA has granted expanded access to a groundbreaking pancreatic cancer drug that has shown unprecedented results in clinical trials, allowing more patients to receive the treatment even before official approval. Drugmaker Revolution Medicine reported that in a clinical trial, metastatic pancreatic cancer patients who took the drug survived a median of 13 months, compared to about six months for similar patients who underwent chemotherapy. The FDA received the expanded access request from Revolution Medicines on April 28 and signed it on April 30.
The medication, called daraxonrasib, represents a major breakthrough for one of medicine's most devastating diseases. The medication, daraxonrasib, is a 300 milligram pill taken once a day. The drug blocks a signal that causes cancer cells to grow non-stop. Daraxonrasib is a RAS inhibitor designed to inhibit a protein (RAS) that is mutated in most pancreatic cancer tumors.
FDA commissioner Marty Makary said the timeline "reflects the FDA's strong commitment to facilitate early access to therapies for serious and life-threatening conditions, including pancreatic cancer." The rapid approval process demonstrates how urgently new treatments are needed for this particularly lethal form of cancer.
Personal Stories of Hope
Former Senator Ben Sasse has become an unexpected advocate for the drug after experiencing dramatic improvements in his own battle with stage-four pancreatic cancer. Former Sen. Ben Sasse, 54, called daraxonrasib "a miracle drug" in a conversation with "60 Minutes" and said it has helped him live longer and with less pain. He was diagnosed with stage-four pancreatic cancer in December.
"I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months," Sasse told Scott Pelley. His experience illustrates the real-world impact this treatment could have for thousands of patients facing similar diagnoses.
Understanding the Crisis
Pancreatic cancer remains one of the deadliest forms of the disease, with survival statistics that have barely improved over decades. The National Cancer Institute predicts that 67,530 new cases of pancreatic cancer will be diagnosed in 2026, and that 52,740 people will die from the disease during the same time. Pancreatic cancer accounts for 8.4% of cancer deaths, despite making up only 3.2% of new cancer cases.
Daraxonrasib is being approved for use under the FDA's expanded access program. Also called "compassionate use," this option allows patients with serious or terminal conditions to take investigational therapies outside of a clinical trial. This mechanism ensures that patients who have exhausted other treatment options can access potentially life-saving therapies while the formal approval process continues.
What This Means for Patients
Per EAP guidelines, requests for expanded access must be submitted to the sponsor by physicians licensed in the U.S. on behalf of eligible patients. This means patients cannot directly request the drug but must work through their oncologists to determine eligibility and submit applications.
The expanded access protocol specifically targets patients with previously treated metastatic pancreatic ductal adenocarcinoma, providing hope for those who have already undergone standard treatments without success. In an interview with CancerNetwork, Diane Simeone, MD, director of the Moores Cancer Center at University of California San Diego Health, said, "This is a substantial benefit for patients with metastatic pancreas cancer, who represent about half of the patients we see. These findings are impactful for improving both the length and quality of life for patients."
As Revolution Medicines prepares to submit their full application for FDA approval, this expanded access program offers immediate hope to patients and families confronting one of cancer's most formidable challenges. The drug's ability to more than double survival times while reducing pain and tumor size represents the kind of breakthrough that could fundamentally change how we treat pancreatic cancer.